Obejective:To compare the diagnostic value of 18F-flurodeoxyglucose(FDG)positron emission tomography(PET)/computed tomography(CT)and 18F-fibroblast activation protein inhibitor(FAPI)PET/CT for patients with suspected recurrence of abdominal and pelvic malignant tumors after treatment.Methods:The clinical follow-up results,pathological data,and 18F-FDG PET/CT and 18F-FAPI PET/CT imaging results of patients with clinically suspected recurrence/metastasis of abdominal and pelvic malignant tumors after treatment who were admitted to the Sun Yat-sen University Cancer Centre from September 2021 to February 2024 were reviewed and analyzed.The patient's medical history and clinical follow-up results were collected.The patient's lesions were measured with the maximum standard uptake value(SUVmax)and calculated the tumor-to-background ratio(TBR).SUVmax and TBR were analyzed by Violin Plot and paired t-test.The diagnostic efficacy of 18F-FDG PET/CT and 18F-FAPI PET/CT was statistically compared.Results:Of the 64 patients(33 males,31 females)with clinically suspected recurrence/metastasis after treatment for abdominal and pelvic malignant tumors,52 had metastasis confirmed by clinical or pathological examination.There was no significant difference in SUVmax between the two images(P>0.05).In the Violin Plot,the median SUVmax of 18F-FAPI PET/CT was higher than that of 18F-FDG PET/CT,and the distribution was more concentrated.TBR was statistically significant(P<0.000 1),and the TBR of 18F-FAPI PET/CT was higher than that of 18F-FDG PET/CT.The sensitivity of 18F-FDG PET/CT and 18F-FAPI PET/CT for diagnosing metastasis was 55.8%(29/52)and 88.5%(46/52),the specificity was 83.3%(10/12)and 58.3%(7/12),and the accuracy was 60.9%(39/64)and 82.8%(53/64),respectively.Conclusion:18F-FAPI PET/CT is superior to 18F-FDG PET/CT for patients with suspected recurrence of abdominal and pelvic malignant tumors after treatment,especially in peritoneal metastases,and can be used as a complementary method when the 18F-FDG-PET/CT is negative,provide more information to the clinic.
Malignant tumor/Abdominal and pelvic/Metastasis/Positron emission tomography/computed tomography/18F-fluorodeoxyglucose/Fibroblast activation protein inhibitor